[Federal Register Volume 83, Number 88 (Monday, May 7, 2018)]
[Notices]
[Pages 20145-20160]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09549]


=======================================================================
-----------------------------------------------------------------------

UNITED STATES SENTENCING COMMISSION


Sentencing Guidelines for United States Courts

AGENCY: United States Sentencing Commission.

ACTION: Notice of submission to Congress of amendments to the 
sentencing guidelines effective November 1, 2018.

-----------------------------------------------------------------------

SUMMARY: Pursuant to its authority, the Commission has promulgated 
amendments to the sentencing guidelines, policy statements, commentary, 
and statutory index. This notice sets forth the amendments and the 
reason for each amendment.

DATES: The Commission has specified an effective date of November 1, 
2018, for the amendments set forth in this notice.

FOR FURTHER INFORMATION CONTACT: Christine Leonard, Director, Office of

[[Page 20146]]

Legislative and Public Affairs, (202) 502-4500, [email protected].

SUPPLEMENTARY INFORMATION: The United States Sentencing Commission is 
an independent agency in the judicial branch of the United States 
Government. The Commission promulgates sentencing guidelines and policy 
statements for federal courts pursuant to 28 U.S.C. 994(a). The 
Commission also periodically reviews and revises previously promulgated 
guidelines pursuant to 28 U.S.C. 994(o) and generally submits guideline 
amendments to the Congress pursuant to 28 U.S.C. 994(p) not later than 
the first day of May each year. Absent action of the Congress to the 
contrary, submitted amendments become effective by operation of law on 
the date specified by the Commission (generally November 1 of the year 
in which the amendments are submitted to Congress).
    Notices of the proposed amendments were published in the Federal 
Register on August 25, 2017 (see 82 FR 40651) and January 26, 2018 (see 
83 FR 3869). The Commission held public hearings on the proposed 
amendments in Washington, DC, on February 8 and March 14, 2018. On 
April 30, 2018, the Commission submitted these amendments to the 
Congress and specified an effective date of November 1, 2018.
    The text of the amendments to the sentencing guidelines, policy 
statements, commentary, and statutory index, and the reason for each 
amendment, are set forth below. Additional information pertaining to 
the amendments described in this notice may be accessed through the 
Commission's website at www.ussc.gov.

    Authority: 28 U.S.C. 994(a), (o), and (p); USSC Rules of 
Practice and Procedure 2.2, 4.1.

William H. Pryor Jr.,
Acting Chair.

Amendments to the Sentencing Guidelines, Policy Statements, and 
Official Commentary

    1. Amendment: The Commentary to Sec.  1B1.1 captioned ``Application 
Notes'' is amended in Note 1 by redesignating paragraphs (D) through 
(L) as paragraphs (E) through (M), respectively; and by inserting the 
following new paragraph (D):
    ``(D) `Court protection order' means `protection order' as defined 
by 18 U.S.C. 2266(5) and consistent with 18 U.S.C. 2265(b).''.
    The Commentary to Sec.  2B3.1 captioned ``Application Notes'' is 
amended in Note 2 by striking ``Application Note 1(D)(ii) of Sec.  
1B1.1'' and inserting ``Application Note 1(E)(ii) of Sec.  1B1.1''.
    The Commentary to Sec.  2L1.1 captioned ``Application Notes'' is 
amended in Note 4 by striking ``Application Note 1(L) of Sec.  1B1.1'' 
and inserting ``Application Note 1(M) of Sec.  1B1.1''.
    Section 4A1.3(a)(2) is amended by striking ``subsection (a)'' and 
inserting ``subsection (a)(1)''; and by striking ``sentences for 
foreign and tribal offenses'' and inserting ``sentences for foreign and 
tribal convictions''.
    The Commentary to Sec.  4A1.3 captioned ``Application Notes'' is 
amended--

in Note 2 by inserting at the end the following new paragraph (C):
    ``(C) Upward Departures Based on Tribal Court Convictions.--In 
determining whether, or to what extent, an upward departure based on a 
tribal court conviction is appropriate, the court shall consider the 
factors set forth in Sec.  4A1.3(a) above and, in addition, may 
consider relevant factors such as the following:
    (i) The defendant was represented by a lawyer, had the right to a 
trial by jury, and received other due process protections consistent 
with those provided to criminal defendants under the United States 
Constitution.
    (ii) The defendant received the due process protections required 
for criminal defendants under the Indian Civil Rights Act of 1968, 
Public Law 90-284, as amended.
    (iii) The tribe was exercising expanded jurisdiction under the 
Tribal Law and Order Act of 2010, Public Law 111-211.
    (iv) The tribe was exercising expanded jurisdiction under the 
Violence Against Women Reauthorization Act of 2013, Public Law 113-4.
    (v) The tribal court conviction is not based on the same conduct 
that formed the basis for a conviction from another jurisdiction that 
receives criminal history points pursuant to this Chapter.
    (vi) The tribal court conviction is for an offense that otherwise 
would be counted under Sec.  4A1.2 (Definitions and Instructions for 
Computing Criminal History).'';

and in Note 3 by striking ``A departure below the lower limit of the 
applicable guideline range for Criminal History Category I is 
prohibited under subsection (b)(2)(B)'' and inserting ``A departure 
below the lower limit of the applicable guideline range for Criminal 
History Category I is prohibited under subsection (b)(2)(A)''.
    Reason for Amendment: This two-part amendment addresses federal 
sentencing issues related to offenses committed in Indian country. The 
amendment responds to the findings and recommendations made by the 
Commission's ad hoc Tribal Issues Advisory Group in its report to the 
Commission. See Report of the Tribal Issues Advisory Group (May 16, 
2016), http://www.ussc.gov/research/research-publications/report-tribal-issues-advisory-group.
    The amendment adds a definition of ``court protection order'' in 
the guidelines. This issue was initially raised by the Commission's 
Victims Advisory Group and subsequently addressed in the Tribal Issues 
Advisory Group's May 2016 report. The amendment amends Sec.  1B1.1 
(Application Instructions) to add a definition of ``court protection 
order'' that incorporates by reference the statutory definition of a 
``protection order'' as set forth in 18 U.S.C. 2266(5) and consistent 
with 18 U.S.C. 2265(b). Under the Guidelines Manual, the violation of a 
court protection order is a specific offense characteristic in three 
Chapter Two offense guidelines. See USSG Sec. Sec.  2A2.2 (Aggravated 
Assault), 2A6.1 (Threatening or Harassing Communications; Hoaxes; False 
Liens), and 2A6.2 (Stalking or Domestic Violence).
    The amendment responds to concerns that the term ``court protection 
order'' has not been defined in the guidelines and should be clarified. 
Providing a clear definition of a ``court protection order'' in the 
Guidelines Manual will ensure that orders used for sentencing 
enhancements are the result of court proceedings assuring appropriate 
due process protections, that there is a consistent identification and 
treatment of such orders, and that such orders issued by tribal courts 
receive treatment consistent with that of other issuing jurisdictions. 
The amendment also makes conforming technical changes to the Commentary 
of Sec. Sec.  2B1.3 (Robbery) and 2L1.1 (Smuggling, Transporting, or 
Harboring an Unlawful Alien).
    The amendment addresses the treatment of tribal court convictions 
in Chapter Four (Criminal History and Criminal Livelihood) of the 
Guidelines Manual. Subsection (i) of Sec.  4A1.2 (Definitions and 
Instructions for Computing Criminal History) provides that sentences 
resulting from tribal court convictions are not counted in calculating 
a defendant's criminal history score but may be considered for an 
upward departure under Sec.  4A1.3 (Departures Based on Inadequacy of 
Criminal History Category (Policy Statement)). Section 4A1.3 provides 
for an upward departure for prior sentences that are not used in 
computing the

[[Page 20147]]

criminal history category, such as sentences for tribal convictions, 
where reliable information suggests that the defendant's criminal 
history category under-represents the seriousness of the defendant's 
prior record.
    Tribal court convictions have been excluded from the criminal 
history score but have been a legitimate basis for upward departure 
since the original guidelines were promulgated in 1987. In recent 
years, some tribal courts have gained enhanced sentencing authority 
under the Tribal Law and Order Act of 2010, Public Law 111-211 (July 
29, 2010), and expanded jurisdiction over non-Indian defendants in 
domestic abuse cases under the Violence Against Women Act 
Reauthorization Act of 2013, Public Law 113-4 (Mar. 7, 2013). Many 
tribal courts have also begun to increase due process protections and 
reliable record-keeping.
    In recognition of these developments, the amendment provides 
additional guidance to courts on how to apply the departure provision 
at Sec.  4A1.3 in cases involving a defendant with a history of tribal 
convictions. Specifically, the amendment amends the Commentary to Sec.  
4A1.3 at Application Note 2(c) to provide the following non-exhaustive 
list of six factors that courts may consider in deciding whether or to 
what extent an upward departure based on a tribal conviction may be 
appropriate:
    (i) The defendant was represented by a lawyer, had the right to a 
trial by jury, and received other due process protections consistent 
with those provided to criminal defendants under the United States 
Constitution.
    (ii) The defendant received the due process protections required 
for criminal defendants under the Indian Civil Rights Act of 1968, 
Public Law 90-284, as amended.
    (iii) The tribe was exercising expanded jurisdiction under the 
Tribal Law and Order Act of 2010, Public Law 111-211.
    (iv) The tribe was exercising expanded jurisdiction under the 
Violence Against Women Reauthorization Act of 2013, Public Law 113-4.
    (v) The tribal court conviction is not based on the same conduct 
that formed the basis for a conviction from another jurisdiction that 
receives criminal history points pursuant to this Chapter.
    (vi) The tribal court conviction is for an offense that otherwise 
would be counted under Sec.  4A1.2 (Definitions and Instructions for 
Computing Criminal History).
    Because of the many cultural and historical differences among 
federally-recognized tribes, and especially among their tribal court 
systems, the Commission determined that--despite recent developments in 
Indian law to enlarge the scope of tribal court jurisdiction and the 
availability of due process in tribal court proceedings--a single 
approach to the consideration of tribal convictions would be difficult 
and could potentially lead to a disparate result among Indian 
defendants in federal courts. The amendment, therefore, reflects the 
Commission's view that additional guidance about how to apply the 
departure provision at Sec.  4A1.3 in cases involving a defendant with 
a history of tribal convictions is appropriate, and that the non-
exhaustive list of factors provides appropriate guidance and a more 
structured analytical framework under Sec.  4A1.3. The Commission 
intends, as informed by the Tribal Issues Advisory Group Report and 
public comment, that none of the factors should be determinative, but 
collectively the factors reflect important considerations to help 
courts balance the rights of defendants, the unique and important 
status of tribal courts, the need to avoid disparate sentences because 
of varying tribal court practices and circumstances, and the goal of 
accurately assessing a defendant's criminal history.
    The amendment also includes two technical changes to Sec.  4A1.3. 
First, the amendment amends Sec.  4A1.3(a)(2)(A) to change the phrase 
``sentences for foreign and tribal offenses'' to ``sentences for 
foreign and tribal convictions'' to track the parallel language in 
Sec.  4A1.2(h) and (i). Second, the amendment makes a clerical change 
in Application Note 3 to correct an inaccurate reference to Sec.  
4A1.3(b)(2)(B).
    2. Amendment: Section 2B1.1(b) is amended by redesignating 
paragraphs (13) through (19) as paragraphs (14) through (20), 
respectively; and by inserting the following new paragraph (13):
    ``(13) If the defendant was convicted under 42 U.S.C. 408(a), 
1011(a), or 1383a(a) and the statutory maximum term of ten years' 
imprisonment applies, increase by 4 levels. If the resulting offense 
level is less than 12, increase to level 12.'';

and in paragraph (17) (as so redesignated) by striking ``subsections 
(b)(2) and (b)(16)(B)'' and inserting ``subsections (b)(2) and 
(b)(17)(B)''.
    The Commentary to Sec.  2B1.1 captioned ``Application Notes'' is 
amended--

by redesignating Notes 11 through 20 as Notes 12 through 21, 
respectively; and by inserting the following new Note 11:
    ``11. Interaction of Subsection (b)(13) and Sec.  3B1.3 (Abuse of 
Position of Trust or Use of Special Skill).--If subsection (b)(13) 
applies, do not apply Sec.  3B1.3.'';

in Note 12 (as so redesignated) by striking ``(b)(14)'' both places 
such term appears and inserting ``(b)(15)'';

in Note 13 (as so redesignated) by striking ``(b)(16)(A)'' both places 
such term appears and inserting ``(b)(17)(A)'';

in Note 14 (as so redesignated) by striking ``(b)(16)(B)'' and 
inserting ``(b)(17)(B)''; by striking ``(b)(16)(B)(i)'' and inserting 
``(b)(17)(B)(i)''; and by striking ``(b)(16)(B)(ii)'' and inserting 
``(b)(17)(B)(ii)'';

in Note 15 (as so redesignated) by striking ``(b)(18)'' both places 
such term appears and inserting ``(b)(19)''; by striking 
``(b)(18)(A)(iii)'' both places such term appears and inserting 
``(b)(19)(A)(iii)''; and by striking ``(b)(16)(B)'' both places such 
term appears and inserting ``(b)(17)(B)'';

in Note 16 (as so redesignated) by striking ``(b)(19)'' each place such 
term appears and inserting ``(b)(20)'';

and in Note 21(B) (as so redesignated) by striking ``(b)(18)(A)(iii)'' 
and inserting ``(b)(19)(A)(iii)''.
    The Commentary to Sec.  2B1.1 captioned ``Background'' is amended 
by striking ``(b)(13)'' and inserting ``(b)(14)''; by striking 
``(b)(15)(B)'' and inserting ``(b)(16)(B)''; by striking ``(b)(16)(A)'' 
and inserting ``(b)(17)(A)''; by striking ``(b)(16)(B)(i)'' and 
inserting ``(b)(17)(B)(i)''; by striking ``Subsection (b)(17) 
implements the directive in section 209'' and inserting ``Subsection 
(b)(18) implements the directive in section 209''; by striking 
``Subsection (b)(18) implements the directive in section 225(b)'' and 
inserting ``Subsection (b)(19) implements the directive in section 
225(b)''; and by striking ``(b)(18)(B)'' and inserting ``(b)(19)(B)''.
    Appendix A (Statutory Index) is amended in the line referenced to 
42 U.S.C. 408 by inserting ``, 2X1.1'' at the end; in the line 
referenced to 42 U.S.C. 1011 by inserting ``, 2X1.1'' at the end; and 
in the line referenced to 42 U.S.C. 1383a(a) by inserting ``, 2X1.1'' 
at the end.
    Reason for Amendment: This amendment responds to the Bipartisan 
Budget Act of 2015 (``the Act''), Public Law 114-74 (Nov. 2, 2015), 
which made numerous changes to the statutes governing Social Security 
fraud offenses at 42 U.S.C. 408, 1011, and 1383a. The Act added new 
subsections criminalizing conspiracy to commit fraud for selected 
substantive offenses already proscribed in Title 42 and added an 
increased statutory penalty provision for certain persons who

[[Page 20148]]

commit fraud offenses under the relevant Social Security programs.
    In response to these statutory changes, the amendment makes changes 
to both Sec.  2B1.1 (Theft, Property Destruction, and Fraud) and 
Appendix A (Statutory Index). The amendment to Sec.  2B1.1 addresses 
the increased penalty provisions of the Act by adding a new specific 
offense characteristic with a 4-level enhancement and a minimum offense 
level of 12 for those defendants subject to a 10-year statutory 
maximum, and adds commentary precluding the application of an 
adjustment under Sec.  3B1.3 (Abuse of Position of Trust or Use of 
Special Skill) when the new enhancement applies. The amendment to 
Appendix A references the new conspiracy subsections to the appropriate 
guidelines.
    First, the amendment adds a specific offense characteristic to 
Sec.  2B1.1 in response to the enhanced penalty provisions of the Act. 
The new enhancement provides for a 4-level increase, as well as a 
minimum offense level of 12, for those defendants convicted under the 
relevant statutes and subject to the 10-year statutory maximum. The 
enhancement reflects both Congress's and the Commission's determination 
regarding the seriousness of these offenses, and further reflects the 
difficulty in calculating the true harm caused by such defendants, 
including the harm to the integrity and financial strength of the 
Social Security program and to legitimate Social Security program 
benefit recipients who face delays as a result of the review of claims 
submitted in these cases. The Commission was also persuaded in its 
determination by the significant administrative efforts and costs 
resulting from the regulatory requirement that the Social Security 
Administration review and redetermine the benefit eligibility for every 
benefit recipient associated with the defendant, whether part of the 
fraudulent conduct or not. The new enhancement reflects the increased 
harm caused by these types of cases compared to those types of fraud 
sentenced under Sec.  2B1.1 for which the loss table more appropriately 
reflects the severity of the offense.
    Similar to other minimum offense levels in Sec.  2B1.1, the minimum 
offense level is intended to account for the difficulty in calculating 
the amount of loss, as well as the unique and non-monetary harms 
associated with offenses sentenced under the Act. As previously 
explained in similar contexts, ``[t]he Commission frequently adopts a 
minimum offense level in circumstances in which, as in these cases, 
loss as calculated by the guidelines is difficult to compute or does 
not adequately account for the harm caused by the offense.'' USSG, App. 
C, Amendment 719 (effective Nov. 1, 2008).
    In establishing the 4-level increase, the Commission also added 
commentary precluding the application of an adjustment under Sec.  
3B1.3 to those defendants who are subject to the Act's increased 
statutory maximum penalty. In the Act, Congress specifically defined 
positions of trust in the context of Social Security fraud by 
subjecting to the increased statutory maximum penalties those 
defendants who were:

a person who receives a fee or other income for services performed in 
connection with any determination with respect to benefits under this 
subchapter (including a claimant representative, translator, or current 
or former employee of the Social Security Administration), or who is a 
physician or other health care provider who submits, or causes the 
submission of, medical or other evidence in connection with any such 
determination. . . .
    The Commission precluded application of Sec.  3B1.3 to these 
defendants because the new 4-level enhancement fully accounts for their 
special position. Addressing the abuse of special position in this 
manner will avoid uncertainty, prolonged sentencing hearings, and 
appeals regarding application of the abuse of trust adjustment to 
offenders subject to the increased statutory maximum penalties of the 
Act.
    Second, the amendment amends Appendix A to reference the new 
conspiracy offenses under 42 U.S.C. 408, 1011, and 1383a to Sec.  2X1.1 
(Attempt, Solicitation, or Conspiracy (Not Covered by a Specific 
Offense Guideline)). The Commission determined that referencing these 
conspiracy provisions to Sec.  2X1.1, as well as the guideline 
referenced in the statutory index for the substantive offense, is 
consistent with the instructions at Sec.  1B1.2 (Applicable 
Guidelines).
    3. Amendment: Section 2D1.1 is amended--

by redesignating subsections (b)(13) through (b)(17) as subsections 
(b)(14) through (b)(18), respectively; and by inserting the following 
new subsection (b)(13):
    ``(13) If the defendant knowingly misrepresented or knowingly 
marketed as another substance a mixture or substance containing 
fentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide) or 
a fentanyl analogue, increase by 4 levels.'';

and in each of subsections (c)(1) through (c)(14) by striking ``of 
Fentanyl'' each place such term appears and inserting ``of Fentanyl (N-
phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] Propanamide)''.
    The annotation to Sec.  2D1.1(c) captioned ``Notes to Drug Quantity 
Table'' is amended by inserting at the end the following new Note (J):
    ``(J) Fentanyl analogue, for the purposes of this guideline, means 
any substance (including any salt, isomer, or salt of isomer thereof), 
whether a controlled substance or not, that has a chemical structure 
that is similar to fentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-
piperidinyl] propanamide).''.
    The Commentary to Sec.  2D1.1 captioned ``Application Notes'' is 
amended--

in Note 6 by striking ``Any reference to a particular controlled 
substance in these guidelines includes all salts, isomers, all salts of 
isomers, and, except as otherwise provided, any analogue of that 
controlled substance'' and inserting ``Except as otherwise provided, 
any reference to a particular controlled substance in these guidelines 
includes all salts, isomers, all salts of isomers, and any analogue of 
that controlled substance''; and by striking ``For purposes of this 
guideline `analogue' has the meaning'' and inserting ``Unless otherwise 
specified, `analogue,' for purposes of this guideline, has the 
meaning'';

in Note 8(D)--

in the table under the heading ``Schedule I or II Opiates*''--

by striking the following two lines:

``1 gm of Alpha-Methylfentanyl = 10 kg of marihuana''

``1 gm of 3-Methylfentanyl = 10 kg of marihuana'';

and by inserting after the line referenced to Fentanyl (N-phenyl-N-[1-
(2-phenylethyl)-4-piperidinyl] Propanamide) the following line:

``1 gm of a Fentanyl Analogue = 10 kg of marihuana'';

in the table under the heading ``Cocaine and Other Schedule I and II 
Stimulants (and their immediate precursors)*'', by striking the 
following line:

``1 gm of Methcathinone = 380 gm of marihuana'';

by inserting after the table under the heading ``Cocaine and Other 
Schedule I and II Stimulants (and their immediate precursors)*'' the 
following new table:
    ``Synthetic Cathinones (except Schedule III, IV, and V Substances)*

1 gm of a synthetic cathinone

(except a Schedule III, IV, or V substance) = 380 gm of marihuana

[[Page 20149]]

    *Provided, that the minimum offense level from the Drug Quantity 
Table for any synthetic cathinone (except a Schedule III, IV, or V 
substance) individually, or in combination with another controlled 
substance, is level 12.'';

by inserting after the table under the heading ``Schedule I Marihuana'' 
the following new table:
    ``Synthetic Cannabinoids (except Schedule III, IV, and V 
Substances)*

1 gm of a synthetic cannabinoid

(except a Schedule III, IV, or V substance) = 167 gm of marihuana
    *Provided, that the minimum offense level from the Drug Quantity 
Table for any synthetic cannabinoid (except a Schedule III, IV, or V 
substance) individually, or in combination with another controlled 
substance, is level 12.
    `Synthetic cannabinoid,' for purposes of this guideline, means any 
synthetic substance (other than synthetic tetrahydrocannabinol) that 
binds to and activates type 1 cannabinoid receptors (CB1 
receptors).'';

    in Note 16 by striking ``Sec.  2D1.1(b)(15)(D)'' and inserting 
``Sec.  2D1.1(b)(16)(D)'';

in Note 18 by striking ``(b)(13)'' and inserting ``(b)(14)''; by 
striking ``(b)(13)(A)'' each place such term appears and inserting 
``(b)(14)(A)''; by striking ``(b)(13)(C)-(D)'' and inserting 
``(b)(14)(C)-(D)''; by striking ``(b)(13)(C)(ii)'' and inserting 
``(b)(14)(C)(ii)''; and by striking ``(b)(13)(D)'' and inserting 
``(b)(14)(D)''.

in Note 19 by striking ``(b)(14)'' each place such term appears and 
inserting ``(b)(15)''; and by striking ``(b)(13)(A)'' and inserting 
``(b)(14)(A)'';

in Note 20 by striking ``(b)(15)'' and inserting ``(b)(16)''; by 
striking ``(b)(15)(B)'' both places such term appears and inserting 
``(b)(16)(B)''; by striking ``(b)(15)(C)'' each place such term appears 
and inserting ``(b)(16)(C)''; and by striking ``(b)(15)(E)'' both 
places such term appears and inserting ``(b)(16)(E)'';

in Note 21 by striking ``(b)(17)'' each place such term appears and 
inserting ``(b)(18)'';

and in Note 27 by inserting at the end the following new paragraphs:
    ``(D) Departure Based on Potency of Synthetic Cathinones.--In 
addition to providing marihuana equivalencies for specific controlled 
substances and groups of substances, the Drug Equivalency Tables 
provide marihuana equivalencies for certain classes of controlled 
substances, such as synthetic cathinones. In the case of a synthetic 
cathinone that is not specifically referenced in this guideline, the 
marihuana equivalency for the class should be used to determine the 
appropriate offense level. However, there may be cases in which a 
substantially lesser or greater quantity of a synthetic cathinone is 
needed to produce an effect on the central nervous system similar to 
the effect produced by a typical synthetic cathinone in the class, such 
as methcathinone or alpha-PVP. In such a case, a departure may be 
warranted. For example, an upward departure may be warranted in cases 
involving MDPV, a substance of which a lesser quantity is usually 
needed to produce an effect on the central nervous system similar to 
the effect produced by a typical synthetic cathinone. In contrast, a 
downward departure may be warranted in cases involving methylone, a 
substance of which a greater quantity is usually needed to produce an 
effect on the central nervous system similar to the effect produced by 
a typical synthetic cathinone.
    (E) Departures for Certain Cases involving Synthetic 
Cannabinoids.--
    (i) Departure Based on Concentration of Synthetic Cannabinoids.--
Synthetic cannabinoids are manufactured as powder or crystalline 
substances. The concentrated substance is then usually sprayed on or 
soaked into a plant or other base material, and trafficked as part of a 
mixture. Nonetheless, there may be cases in which the substance 
involved in the offense is a synthetic cannabinoid not combined with 
any other substance. In such a case, an upward departure would be 
warranted.
    There also may be cases in which the substance involved in the 
offense is a mixture containing a synthetic cannabinoid diluted with an 
unusually high quantity of base material. In such a case, a downward 
departure may be warranted.
    (ii) Downward Departure Based on Potency of Synthetic 
Cannabinoids.--In the case of a synthetic cannabinoid that is not 
specifically referenced in this guideline, the marihuana equivalency 
for the class should be used to determine the appropriate offense 
level. However, there may be cases in which a substantially greater 
quantity of a synthetic cannabinoid is needed to produce an effect on 
the central nervous system similar to the effect produced by a typical 
synthetic cannabinoid in the class, such as JWH-018 or AM-2201. In such 
a case, a downward departure may be warranted.''.
    The Commentary to Sec.  2D1.1 captioned ``Background'' is amended 
by striking ``(b)(13)(A)'' and inserting ``(b)(14)(A)''; by striking 
``(b)(13)(C)(ii)'' and inserting ``(b)(14)(C)(ii)''; by striking 
``Subsection (b)(15) implements the directive to the Commission in 
section 6(3)'' and inserting ``Subsection (b)(16) implements the 
directive to the Commission in section 6(3)''; and by striking 
``Subsection (b)(16) implements the directive to the Commission in 
section 7(2)'' and inserting ``Subsection (b)(17) implements the 
directive to the Commission in section 7(2)''.
    The Commentary to Sec.  2D1.6 captioned ``Application Note'' is 
amended in Note 1 by striking ``, fentanyl'' and inserting ``, fentanyl 
(N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide)''.
    Section 2D1.14(a)(1) is amended by striking ``(b)(17)'' and 
inserting ``(b)(18)''.
    The Commentary to Sec.  3B1.4 captioned ``Application Notes'' is 
amended in Note 2 by striking ``Sec.  2D1.1(b)(15)(B)'' and inserting 
``Sec.  2D1.1(b)(16)(B)''.
    The Commentary to Sec.  3C1.1 captioned ``Application Notes'' is 
amended in Note 7 by striking ``Sec.  2D1.1(b)(15)(D)'' and inserting 
``Sec.  2D1.1(b)(16)(D)''.
    Reason for Amendment: This amendment is a result of the 
Commission's multi-year study of offenses involving synthetic 
cathinones (such as methylone, MDPV, and mephedrone) and synthetic 
cannabinoids (such as JWH-018 and AM-2201), as well as 
tetrahydrocannabinol (THC), fentanyl, and fentanyl analogues. The study 
included extensive data collection, review of scientific literature, 
multiple public comment periods, and four public hearings. The 
resulting amendment makes various changes to Sec.  2D1.1 pertaining to 
synthetic controlled substances.
    The amendment first addresses fentanyl and fentanyl analogues. The 
Commission learned that while fentanyl has long been a drug of abuse, 
there are several indications that its abuse has become both more 
prevalent and more dangerous in recent years. For example, the Drug 
Enforcement Administration observed a dramatic increase in fentanyl 
reports between 2013 and 2015, and the Centers for Disease Control and 
Prevention reported that there were 9,580 deaths involving synthetic 
opioids (a category including fentanyl) in 2015, a 72.2 percent 
increase from 2014. The Commission received testimony and other 
information indicating that fentanyl and its analogues are often 
trafficked mixed with other controlled substances, including heroin and 
cocaine. In other instances, fentanyl is placed in pill or tablet form 
by drug traffickers. Although some purchasers of these substances may 
be aware that they

[[Page 20150]]

contain fentanyl (or even seek them out for that reason), others may 
believe that they are purchasing heroin or pharmaceutically 
manufactured opioid pain relievers.
    Because of fentanyl's extreme potency, the risk of overdose death 
is great, particularly when the user is inexperienced or unaware of 
what substance he or she is using. To address this harm, the amendment 
adds a new specific offense characteristic at Sec.  2D1.1(b)(13) to 
provide for a 4-level increase whenever the defendant knowingly 
misrepresented or knowingly marketed as another substance a mixture or 
substance containing fentanyl or a fentanyl analogue. The Commission 
determined that it is appropriate for traffickers who knowingly 
misrepresent fentanyl or a fentanyl analogue as another substance to 
receive additional punishment. If an offender does not know the 
substance contains fentanyl or a fentanyl analogue, the enhancement 
does not apply. The specific offense characteristic includes a mens rea 
requirement to ensure that only the most culpable offenders are 
subjected to these increased penalties.
    The amendment also makes a definitional change in the Guidelines 
Manual. Title 21, United States Code, refers to fentanyl by reference 
to its chemical name (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] 
propanamide) and sets mandatory minimum penalties for certain 
quantities of this substance and for analogues of N-phenyl-N-[1-(2-
phenylethyl)-4-piperidinyl] propanamide, although lesser quantities of 
the analogues are required to trigger the mandatory minimum penalties. 
See, e.g., 21 U.S.C. 841(b)(1)(A)(vi). Consistent with its past 
practice concerning setting drug-trafficking penalties, the Commission 
relied upon the statutory framework in setting penalties for fentanyl 
and fentanyl analogues. Fentanyl has a marihuana equivalency of 
1:2,500, while fentanyl analogues have a marihuana equivalency of 
1:10,000. In the Guidelines Manual, however, the Commission did not use 
the chemical name for fentanyl reflected in Title 21. Instead, the 
Commission used the terms ``fentanyl'' and ``fentanyl analogue'' in the 
Drug Quantity Table.
    Commission data suggests that offenses involving fentanyl analogues 
are increasing in the federal caseload. In studying these cases, the 
Commission has learned that the reference to ``fentanyl analogue'' in 
the Drug Quantity Table may interact in an unintended way with the 
definition of ``analogue'' provided by Application Note 6 and Section 
802(32) of Title 21, United States Code. Because the guideline 
incorporates by reference the statutory definition of ``controlled 
substance analogue,'' and that definition specifically excludes already 
listed ``controlled substances,'' it appears that a scheduled fentanyl 
analogue cannot constitute a ``controlled substance analogue,'' and 
thus does not constitute a fentanyl ``analogue'' for purposes of Sec.  
2D1.1. This may have the result that, at sentencing, fentanyl analogues 
that have already been scheduled must go through the Application Note 6 
process to determine the substance most closely related to them.
    Additionally, based on implementation of Application Note 6, many 
courts have then sentenced such analogue cases at the lower fentanyl 
ratio rather than the higher ratio applicable to fentanyl analogues in 
the Drug Quantity Table. To address this problem, the amendment adopts 
a new definition of ``fentanyl analogue'' as ``any substance (including 
any salt, isomer, or salt of isomer), whether a controlled substance or 
not, that has a chemical structure that is similar to fentanyl (N-
phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide).'' This portion 
of the amendment also amends the Drug Quantity Table to clarify that 
Sec.  2D1.1 uses the term ``fentanyl'' to refer to the chemical name 
identified by statute and deletes the current listings for alpha-
methylfentanyl and 3-methylfentanyl from the Drug Equivalency Tables.
    The Commission determined that adopting this definition of 
``fentanyl analogue'' will create a class of fentanyl analogues 
identical to that already created by statute, clarify the legal 
confusion that has resulted from the current definition of ``analogue'' 
in Sec.  2D1.1, and reaffirm that fentanyl analogues are treated 
differently than fentanyl under the guidelines as well as the statute. 
Striking the separate references to alpha-methylfentanyl and 3-
methylfentanyl will result in the treatment of these substances in 
common with all other fentanyl analogues. This change, in combination 
with the adoption of the definition of ``fentanyl analogue'' and 
addition of fentanyl analogue to the Drug Equivalency Tables, will 
limit the use of the listing for ``fentanyl'' to those cases involving 
the specific substance named in Title 21.
    Next, the amendment addresses synthetic cathinones and synthetic 
cannabinoids. The Commission received comment from the Department of 
Justice and others expressing concern that the guidelines do not 
contain specific ``marihuana equivalencies'' for synthetic cathinones, 
such as methylone, mephedrone, and MDPV, or synthetic cannabinoids, 
such as JWH-018 and AM-2201. For substances that do not appear in 
either the Drug Quantity Table or the Drug Equivalency Table, 
Application Note 6 provides courts the process for calculating drug 
quantities. The note directs courts to identify the ``most closely 
related controlled substance referenced in [Sec.  2D1.1]'' and to then 
use that drug's ratio to marihuana to calculate the quantity for 
purposes of determining the base offense level. Commenters advised that 
this process is a time-consuming, burdensome task that leads to 
sentencing disparities. Because Commission data indicated that the 
majority of cases relying on the Application Note 6 process involved 
synthetic cathinones and synthetic cannabinoids, the Commission 
concluded that this amendment will alleviate the burden associated with 
its application.
    Synthetic cathinones, also known as ``bath salts,'' are human-made 
substances chemically related to cathinone, a stimulant found in the 
khat plant. Although the Commission's study originally focused on 
specified cathinones, such as methylone, MDPV, and mephedrone, the 
Commission received comments indicating that new substances are 
regularly developed and trafficked and that it would not be feasible to 
establish a new ratio as each new substance enters the market. Given 
the large number of potential substances, the Commission found it 
impracticable to add individual marihuana equivalencies for every 
synthetic cathinone. In contrast, the Commission determined a class-
based approach for synthetic cathinones should capture both current and 
future synthetic cathinones.
    The Commission has determined that synthetic cathinones constitute 
a well-defined class. Specifically, testimony and comment presented to 
the Commission consistently indicated that the whether a substance is a 
synthetic cathinone is not subject to debate. Likewise, comments and 
testimony made clear that synthetic cathinones share stimulant 
characteristics and hallucinogenic effects. The Commission determined 
that a precise definition is not necessary for such substances and that 
a class-based structure could be reasonably adopted. The Commission 
likewise determined that, because the class would encompass 
methcathinone, currently the lone specifically listed synthetic 
cathinone, the separate reference to methcathinone in the Drug

[[Page 20151]]

Equivalency Table should be deleted. Given the Commission's priority to 
alleviate the burdens associated with the Application Note 6 process 
and the impracticality of adding many new marihuana equivalencies, the 
Commission concluded the class-based approach strikes a middle ground 
between precision and ease of guideline application.
    The amendment creates an entry in the Drug Equivalency Tables for 
the class of synthetic cathinones, providing a marihuana equivalency of 
1 gram of a synthetic cathinone (except a Schedule III, IV, or V 
substance) equals 380 grams of marihuana and applies a minimum base 
offense level of 12 to the class of synthetic cathinones. The 
Commission set a minimum base offense level of 12 for the class of 
synthetic cathinones to maintain consistency with the treatment of 
other controlled substances. With limited exceptions, all other 
Schedule I and II controlled substances are subject to the same minimum 
base offense level. The Commission was not presented with testimony or 
commentary that indicated a compelling basis to except synthetic 
cathinones from the minimum offense level.
    The Commission adopted the 380-gram equivalency for three reasons. 
First, a review of the Commission's data indicated that the 380-gram 
equivalency was both the median and approximate mean ratio utilized by 
the courts when sentencing synthetic cathinone cases pursuant to 
Application Note 6. Thus, the Commission determined that the 380-gram 
equivalency best reflects the current sentencing practices for courts 
engaging in the Application Note 6 analysis.
    Second, the Commission concluded that a ratio consistent with the 
existing methcathinone ratio was appropriate. The Commission set the 
methcathinone ratio based upon a scientific study that found that 
methcathinone was approximately 1.92 times more potent than 
amphetamine. At the time, amphetamine had a marihuana equivalency of 
1:200, equivalent to the current marihuana equivalency of cocaine. The 
Commission's current study of cathinones did not uncover any new 
scientific evidence undermining its rationale for setting the 
methcathinone ratio.
    Third, the Commission was presented with substantial information 
about synthetic cathinones' risks. Testimony before the Commission 
established that the effects and potencies of synthetic cathinones 
range from ``at least as dangerous as cocaine'' to methamphetamine-
like. Medical experts discussed the substantial potential health 
impacts of cathinone use, while law enforcement witnesses offered 
reports of cathinone users' aggressive behavior posing threats to first 
responders. With cocaine at a 1:200 ratio and methamphetamine at a 
1:2,000 ratio, the Commission concluded that the ratio of 1:380 
minimized the risk of frequent over-punishment for substances in this 
class while providing penalty levels sufficient to account for the 
specific harms caused by distribution of these substances.
    In adopting a class-based approach for both ease of application and 
because of the impracticability of listing every new substance in the 
class as it enters the market, the Commission recognizes, however, that 
some substances may be significantly more or less potent than the 
typical substances in the class that the ratio was intended to reflect. 
Therefore, the Commission added a departure provision to address those 
substances for which a greater or lesser quantity is needed to produce 
an effect on the central nervous system similar to the effect produced 
by a typical synthetic cathinone.
    To provide guidance to the court in determining whether to apply 
the departure, the departure provision identifies substances that the 
Commission found to be fair representatives of the synthetic cathinones 
that would fall within the spectrum of substances included in the 
class, as well as those that may warrant a departure. Specifically, the 
departure provision notes that: A typical cathinone has a potency 
comparable to methcathinone or alpha-PVP; methylone is an example of a 
lower potency substance; and MDPV is an example of a higher potency 
substance.
    Synthetic cannabinoids mimic the effects of tetrahydrocannabinol 
(``THC''), the main psychoactive chemical in marihuana. Unlike THC, 
however, most synthetic cannabinoids are ``full agonists.'' That is, 
they activate the body's type 1 cannabinoid receptors (CB1) 
to a greater degree (i.e., at 100%) than THC, which activates the 
CB1 receptors only at 30 to 50 percent. Additionally, unlike 
THC, synthetic cannabinoids do not contain the additional substances 
that moderate their adverse effects. To the contrary, they may contain 
additional substances that augment their hallucinogenic effects. 
Further, some forms of packaged mixtures (e.g., ``K2'', ``Spice'') may 
contain preservatives, additives, and other chemicals such as 
benzodiazepines that may compound the adverse effects caused by the 
cannabinoids. Also unlike THC, synthetic cannabinoids have been 
associated with physical harms such as organ failure and death.
    Through the Commission's multi-year synthetic drug study, the 
Commission learned that hundreds of synthetic cannabinoids exist. When 
first marketed, synthetic cannabinoids generally have not yet been 
scheduled as controlled substances. Often, once a synthetic cannabinoid 
is scheduled, a new one is created to replace it. Given the large 
number of potential substances, the Commission found it impracticable 
to add individual marihuana equivalencies for every synthetic 
cannabinoid. In contrast, the Commission determined that a class-based 
approach for synthetic cannabinoids would be a better means to capture 
both current and future synthetic cannabinoids.
    Based on hearing testimony, the scientific literature, and public 
comment, the Commission determined that all synthetic cannabinoids can 
be covered by a single class because these substances share a similar 
pharmacological effect: All synthetic cannabinoids bind to and activate 
the CB1 receptor. Given the Commission's priority to 
alleviate the burdens associated with the Application Note 6 process 
and the impracticality of adding many new marihuana equivalencies, the 
Commission concluded the class-based approach strikes a middle ground 
between precision and ease of guideline application.
    The amendment defines the term ``synthetic cannabinoid'' as ``any 
synthetic substance (other than synthetic tetrahydrocannabinol) that 
binds to and activates type 1 cannabinoid receptors (CB1 
receptors).'' The amendment establishes a marihuana equivalency for the 
class of synthetic cannabinoids of 1 gram of a synthetic cannabinoid 
(except a Schedule III, IV, or V substance) equals 167 grams of 
marihuana and applies a minimum base offense level of 12 to the class.
    The marihuana equivalency selected for the class is identical to 
the existing marihuana equivalencies for both organic and synthetic 
tetrahydrocannabinol (THC). The Commission originally derived the 
organic and synthetic THC equivalencies from a comparison of standard 
dosage units of THC (3 mg) and marihuana (500 mg) and the relationship 
between the two, rather than the actual amount of THC commonly found in 
a dose of marihuana. During its current study, the Commission 
considered whether to incorporate THC (synthetic) into the new 
synthetic cannabinoid class. As

[[Page 20152]]

noted, the new synthetic cannabinoid class will be subject to the 
minimum base offense level of 12 applicable to most Schedule I and II 
controlled substances. The Commission set a minimum base offense level 
of 12 to the class for consistency with other Schedule I and II 
controlled substances. THC (synthetic) is not currently subject to the 
same minimum offense level. Thus, incorporating THC (synthetic) into 
the synthetic cannabinoid class would effectively change penalties for 
certain THC (synthetic) offenses, an outcome contrary to the 
Commission's intent. Consequently, THC (synthetic) is exempted from the 
class, its separate marihuana equivalency is retained, and that 
equivalency is applicable only in cases involving THC (synthetic).
    Nevertheless, the Commission used the same marihuana equivalency 
for the class of synthetic cannabinoids. Commission data for cases 
involving synthetic cannabinoids indicates that the courts almost 
uniformly apply the marihuana equivalency for THC to such cases. Hence, 
the 1:167 ratio for the synthetic cannabinoid class reflects the 
courts' current sentencing practices. Although synthetic cannabinoids 
activate the CB1 receptor to a greater degree than THC, the 
evidence also established that synthetic cannabinoids exhibit a range 
of potencies. Those most frequently encountered in the Commission's 
data exhibited potencies ranging from one to six times that of THC. 
Adoption of the existing THC marihuana equivalency minimizes the risk 
of frequent over-punishment for substances in this class while 
providing penalty levels that are sufficient to account for the 
specific harms caused by distribution of these substances.
    Finally, the amendment provides two departure provisions addressing 
synthetic cannabinoids. First, the amendment provides for a departure 
based on the concentration of a synthetic cannabinoid. The Commission 
learned that synthetic cannabinoids are manufactured as a powder or 
crystalline substance and are typically sprayed on or mixed with inert 
material (such as plant matter) before retail sale. As a result, a 
synthetic cannabinoid seized after it has been prepared for retail sale 
will typically weigh significantly more than the undiluted form of the 
same controlled substance.
    Given the central role of drug quantity in setting the base offense 
level, an individual convicted of an offense involving a synthetic 
cannabinoid mixture would likely be subject to a guideline penalty 
range significantly higher than another individual convicted of an 
offense involving an undiluted synthetic cannabinoid (but who could 
nevertheless produce an equivalent amount of consumable product). In a 
case involving undiluted synthetic cannabinoid, an upward departure may 
be appropriate for that reason. By contrast, in a case where the 
mixture containing synthetic cannabinoids contained a high quantity of 
inert material, a downward departure may be warranted.
    The second departure provision provides that a downward departure 
may be appropriate where a substantially greater quantity of the 
synthetic cannabinoid involved in the offense is needed to produce an 
effect on the central nervous system similar to the effect produced by 
a typical synthetic cannabinoid in the class. The two synthetic 
cannabinoids specifically cited in the Commission's priority, JWH-018 
and AM-2201, are three and a half times and five times more potent, 
respectively, than THC. If an offense involves a substantially less 
potent synthetic cannabinoid than JWH-018 or AM-2201, the court may 
wish to consider whether a downward departure is appropriate.
    4. Amendment: The Commentary to Sec.  1B1.10 captioned 
``Application Notes'' is amended in Note 5 by striking ``Drug 
Equivalency Tables'' and inserting ``Drug Equivalency Tables (currently 
called Drug Conversion Tables)''.
    Section 2D1.1(c)(1), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  90,000 KG or more of Converted Drug Weight.''.
    Section 2D1.1(c)(2), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 30,000 KG but less than 90,000 KG of Converted 
Drug Weight.''.
    Section 2D1.1(c)(3), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 10,000 KG but less than 30,000 KG of Converted 
Drug Weight.''.
    Section 2D1.1(c)(4), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 3,000 KG but less than 10,000 KG of Converted 
Drug Weight.''.
    Section 2D1.1(c)(5), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 1,000 KG but less than 3,000 KG of Converted 
Drug Weight.''.
    Section 2D1.1(c)(6), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 700 KG but less than 1,000 KG of Converted 
Drug Weight.''.
    Section 2D1.1(c)(7), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 400 KG but less than 700 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(8), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 100 KG but less than 400 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(9), as amended by Amendment 3 of this document, is 
further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 80 KG but less than 100 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(10), as amended by Amendment 3 of this document, 
is further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 60 KG but less than 80 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(11), as amended by Amendment 3 of this document, 
is further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 40 KG but less than 60 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(12), as amended by Amendment 3 of this document, 
is

[[Page 20153]]

further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 20 KG but less than 40 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(13), as amended by Amendment 3 of this document, 
is further amended by striking the period at the end of the line 
referenced to Flunitrazepam and inserting a semicolon; and by adding at 
the end the following:
    ``  At least 10 KG but less than 20 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(14), as amended by Amendment 3 of this document, 
is further amended by striking the period at the end of the line 
referenced to Schedule IV substances (except Flunitrazepam) and 
inserting a semicolon; and by adding at the end the following:
    ``  At least 5 KG but less than 10 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(15) is amended by striking the period at the end 
of the line referenced to Schedule IV substances (except Flunitrazepam) 
and inserting a semicolon, and by adding at the end the following:
    ``  At least 2.5 KG but less than 5 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(16) is amended by striking the period at the end 
of the line referenced to Schedule V substances and inserting a 
semicolon; and by adding at the end the following:
    ``  At least 1 KG but less than 2.5 KG of Converted Drug 
Weight.''.
    Section 2D1.1(c)(17) is amended by striking the period at the end 
of the line referenced to Schedule V substances and inserting a 
semicolon; and by adding at the end the following:
    ``  Less than 1 KG of Converted Drug Weight.''.
    The annotation to Sec.  2D1.1(c) captioned ``Notes to Drug Quantity 
Table'', as amended by Amendment 3 of this document, is further amended 
by inserting at the end the following new Note (K):
    ``(K) The term `Converted Drug Weight,' for purposes of this 
guideline, refers to a nominal reference designation that is used as a 
conversion factor in the Drug Conversion Tables set forth in the 
Commentary below, to determine the offense level for controlled 
substances that are not specifically referenced in the Drug Quantity 
Table or when combining differing controlled substances.''.
    The Commentary to Sec.  2D1.1 captioned ``Application Notes'', as 
amended by Amendment 3 of this document, is further amended--

in Note 6 by striking ``marihuana equivalency'' and inserting 
``converted drug weight''; and by inserting after ``the most closely 
related controlled substance referenced in this guideline.'' the 
following: ``See Application Note 8.'';

in the heading of Note 8 by striking ``Drug Equivalency Tables'' and 
inserting ``Drug Conversion Tables'';

in Note 8(A) by striking ``Drug Equivalency Tables'' both places such 
term appears and inserting ``Drug Conversion Tables''; by striking ``to 
convert the quantity of the controlled substance involved in the 
offense to its equivalent quantity of marihuana'' and inserting ``to 
find the converted drug weight of the controlled substance involved in 
the offense''; by striking ``Find the equivalent quantity of 
marihuana'' and inserting ``Find the corresponding converted drug 
weight''; by striking ``Use the offense level that corresponds to the 
equivalent quantity of marihuana'' and inserting ``Use the offense 
level that corresponds to the converted drug weight determined above''; 
by striking ``an equivalent quantity of 5 kilograms of marihuana'' and 
inserting ``5 kilograms of converted drug weight''; and by striking 
``the equivalent quantity of marihuana would be 500 kilograms'' and 
inserting ``the converted drug weight would be 500 kilograms'';

in Note 8(B) by striking ``Drug Equivalency Tables'' each place such 
term appears and inserting ``Drug Conversion Tables''; by striking 
``convert each of the drugs to its marihuana equivalent'' and inserting 
``convert each of the drugs to its converted drug weight''; by striking 
``For certain types of controlled substances, the marihuana 
equivalencies'' and inserting ``For certain types of controlled 
substances, the converted drug weights assigned''; by striking ``e.g., 
the combined equivalent weight of all Schedule V controlled substances 
shall not exceed 2.49 kilograms of marihuana'' and inserting ``e.g., 
the combined converted weight of all Schedule V controlled substances 
shall not exceed 2.49 kilograms of converted drug weight''; by striking 
``determine the marihuana equivalency for each schedule separately'' 
and inserting ``determine the converted drug weight for each schedule 
separately''; and by striking ``Then add the marihuana equivalencies to 
determine the combined marihuana equivalency'' and inserting ``Then add 
the converted drug weights to determine the combined converted drug 
weight'';

in Note 8(C)(i) by striking ``of marihuana'' each place such term 
appears and inserting ``of converted drug weight''; and by striking 
``The total is therefore equivalent to 95 kilograms'' and inserting 
``The total therefore converts to 95 kilograms'';

in Note 8(C)(ii) by striking the following:
    ``The defendant is convicted of selling 500 grams of marihuana 
(Level 6) and 10,000 units of diazepam (Level 6). The diazepam, a 
Schedule IV drug, is equivalent to 625 grams of marihuana. The total, 
1.125 kilograms of marihuana, has an offense level of 8 in the Drug 
Quantity Table.'',

and inserting the following:
    ``The defendant is convicted of selling 500 grams of marihuana 
(Level 6) and 10,000 units of diazepam (Level 6). The marihuana 
converts to 500 grams of converted drug weight. The diazepam, a 
Schedule IV drug, converts to 625 grams of converted drug weight. The 
total, 1.125 kilograms of converted drug weight, has an offense level 
of 8 in the Drug Quantity Table.'';

in Note 8(C)(iii) by striking ``is equivalent'' both places such term 
appears and inserting ``converts''; by striking ``of marihuana'' each 
place such term appears and inserting ``of converted drug weight''; and 
by striking ``The total is therefore equivalent'' and inserting ``The 
total therefore converts'';

in Note 8(C)(iv) by striking ``marihuana equivalency'' each place such 
term appears and inserting ``converted drug weight''; by striking ``76 
kilograms of marihuana'' and inserting ``76 kilograms''; by striking 
``79.99 kilograms of marihuana'' both places such term appears and 
inserting ``79.99 kilograms of converted drug weight''; by striking 
``equivalent weight'' each place such term appears and inserting 
``converted weight''; by striking ``9.99 kilograms of marihuana'' and 
inserting ``9.99 kilograms''; and by striking ``2.49 kilograms of 
marihuana'' and inserting ``2.49 kilograms'';

in Note 8(D)--

in the heading, by striking ``Drug Equivalency Tables'' and inserting 
``Drug Conversion Tables'';

under the heading relating to Schedule I or II Opiates, by striking the 
heading as follows:

``Schedule I or II Opiates*'',

and inserting the following new heading:

``Schedule I or II Opiates* Converted Drug Weight'';

and by striking ``of marihuana'' each place such term appears;


[[Page 20154]]


under the heading relating Cocaine and Other Schedule I and II 
Stimulants (and their immediate precursors), by striking the heading as 
follows:

``Cocaine and Other Schedule I and II Stimulants (and their immediate 
precursors)*'',

and inserting the following new heading:

``Cocaine and Other Schedule I and II Stimulants (and their immediate 
precursors)* Converted Drug Weight'';

and by striking ``of marihuana'' each place such term appears;

under the heading relating to Synthetic Cathinones (except Schedule 
III, IV, and V Substances), by striking the heading as follows:

``Synthetic Cathinones (except Schedule III, IV, and V Substances)*'',

and inserting the following new heading:

``Synthetic Cathinones (except Schedule III, IV, and V Substances)* 
Converted Drug Weight'';

and by striking ``of marihuana'';

under the heading relating to LSD, PCP, and Other Schedule I and II 
Hallucinogens (and their immediate precursors), by striking the heading 
as follows:

``LSD, PCP, and Other Schedule I and II Hallucinogens (and their 
immediate precursors)*'',

and inserting the following new heading:

``LSD, PCP, and Other Schedule I and II Hallucinogens (and their 
immediate precursors)* Converted Drug Weight'';

and by striking ``of marihuana'' each place such term appears;

under the heading relating to Schedule I Marihuana, by striking the 
heading as follows:

``Schedule I Marihuana'',

and inserting the following new heading:

``Schedule I Marihuana Converted Drug Weight'';

and by striking ``of marihuana'' each place such term appears;

under the heading relating to Synthetic Cannabinoids (except Schedule 
III, IV, and V Substances), by striking the heading as follows:

``Synthetic Cannabinoids (except Schedule III, IV, and V 
Substances)*'',

and inserting the following new heading:

``Synthetic Cannabinoids (except Schedule III, IV, and V Substances)* 
Converted Drug Weight'';

and by striking ``of marihuana'';

under the heading relating to Flunitrazepam, by striking the heading as 
follows:

``Flunitrazepam**'',

and inserting the following new heading:

``Flunitrazepam** Converted Drug Weight'';

and by striking ``of marihuana'';

under the heading relating to Schedule I or II Depressants (except 
gamma-hydroxybutyric acid), by striking the heading as follows:

``Schedule I or II Depressants (except gamma-hydroxybutyric acid)'',

and inserting the following new heading:

``Schedule I or II Depressants (except gamma-hydroxybutyric acid) 
Converted Drug Weight'';

and by striking ``of marihuana'';

under the heading relating to Gamma-hydroxybutyric Acid, by striking 
the heading as follows:

``Gamma-hydroxybutyric Acid'',

and inserting the following new heading:

``Gamma-hydroxybutyric Acid Converted Drug Weight'';

and by striking ``of marihuana'';

under the heading relating to Schedule III Substances (except 
ketamine), by striking the heading as follows:

``Schedule III Substances (except ketamine)***'',

and inserting the following new heading:

``Schedule III Substances (except ketamine)*** Converted Drug Weight'';

by striking ``1 gm of marihuana'' and inserting ``1 gm''; by striking 
``equivalent weight'' and inserting ``converted weight''; and by 
striking ``79.99 kilograms of marihuana'' and inserting ``79.99 
kilograms of converted drug weight'';

under the heading relating to Ketamine, by striking the heading as 
follows:

``Ketamine'',

and inserting the following new heading:

``Ketamine Converted Drug Weight'';

and by striking ``of marihuana'';

under the heading relating to Schedule IV Substances (except 
flunitrazepam), by striking the heading as follows:

``Schedule IV Substances (except flunitrazepam)*****'',

and inserting the following new heading:

``Schedule IV Substances (except flunitrazepam)**** Converted Drug 
Weight'';

by striking ``0.0625 gm of marihuana'' and inserting ``0.0625 gm''; and 
by striking ``*****Provided, that the combined equivalent weight of all 
Schedule IV (except flunitrazepam) and V substances shall not exceed 
9.99 kilograms of marihuana.'' and inserting ``****Provided, that the 
combined converted weight of all Schedule IV (except flunitrazepam) and 
V substances shall not exceed 9.99 kilograms of converted drug 
weight.'';

under the heading relating to Schedule V Substances, by striking the 
heading as follows:

``Schedule V Substances******'',

and inserting the following new heading:

``Schedule V Substances***** Converted Drug Weight'';

by striking ``0.00625 gm of marihuana'' and inserting ``0.00625 gm''; 
and by striking ``******Provided, that the combined equivalent weight 
of Schedule V substances shall not exceed 2.49 kilograms of 
marihuana.'' and inserting ``*****Provided, that the combined converted 
weight of Schedule V substances shall not exceed 2.49 kilograms of 
converted drug weight.'';

under the heading relating to List I Chemicals (relating to the 
manufacture of amphetamine or methamphetamine), by striking the heading 
as follows:

``List I Chemicals (relating to the manufacture of amphetamine or 
methamphetamine)*******'',

and inserting the following new heading:

``List I Chemicals (relating to the manufacture of amphetamine or 
methamphetamine)****** Converted Drug Weight'';

by striking ``of marihuana'' each place such term appears; and by 
striking ``*******Provided, that in a case involving'' and inserting 
``******Provided, that in a case involving'';

under the heading relating to Date Rape Drugs (except flunitrazepam, 
GHB, or ketamine), by striking the heading as follows:

``Date Rape Drugs (except flunitrazepam, GHB, or ketamine)'',

and inserting the following new heading:

``Date Rape Drugs

(except flunitrazepam, GHB, or ketamine) Converted Drug Weight'';

and by striking ``marihuana'' both places such term appears;

and in the text before the heading relating to Measurement Conversion 
Table, by striking ``To facilitate

[[Page 20155]]

conversions to drug equivalencies'' and inserting ``To facilitate 
conversions to converted drug weight'';

in Note 27(D) by striking ``marihuana equivalencies'' both place such 
term appears and inserting ``converted drug weights''; by striking 
``Drug Equivalency Tables'' and inserting ``Drug Conversion Tables''; 
and by striking ``marihuana equivalency'' and inserting ``converted 
drug weight'';

and in Note 27(E)(ii) by striking ``marihuana equivalency'' and 
inserting ``converted drug weight''.
    The Commentary to Sec.  2D1.1 captioned ``Background'', as amended 
by Amendment 3 of this document, is further amended by adding at the 
end the following new paragraph:
    ``The Drug Conversion Tables set forth in Application Note 8 were 
previously called the Drug Equivalency Tables. In the original 1987 
Guidelines Manual, the Drug Equivalency Tables provided four conversion 
factors (or `equivalents') for determining the base offense level in 
cases involving either a controlled substance not referenced in the 
Drug Quantity Table or multiple controlled substances: heroin, cocaine, 
PCP, and marihuana. In 1991, the Commission amended the Drug 
Equivalency Tables to provide for one substance, marihuana, as the 
single conversion factor in Sec.  2D1.1. See USSG App. C, Amendment 396 
(effective November 1, 1991). In 2018, the Commission amended Sec.  
2D1.1 to replace marihuana as the conversion factor with the new term 
`converted drug weight' and to change the title of the Drug Equivalency 
Tables to the `Drug Conversion Tables.' ''.
    The Commentary to Sec.  2D1.11 captioned ``Application Notes'' is 
amended in Note 9 by striking ``Drug Equivalency Table'' and inserting 
``Drug Conversion Table''.
    The Concluding Commentary to Part D of Chapter Three is amended in 
Example 2 by striking ``marihuana equivalents'' and inserting 
``converted drug weight''; by striking ``Drug Equivalency Tables'' and 
inserting ``Drug Conversion Tables''; and by striking ``of marihuana'' 
each place such term appears and inserting ``of converted drug 
weight''.
    Reason for Amendment: This amendment makes technical changes to 
Sec.  2D1.1 (Unlawful Manufacturing, Importing, Exporting, or 
Trafficking (Including Possession with Intent to Commit These 
Offenses); Attempt or Conspiracy). It replaces the term ``marihuana 
equivalency,'' which is used in the Drug Equivalency Tables for 
determining penalties for controlled substances that are not 
specifically referenced in the Drug Quantity Table or when combining 
differing controlled substances, with the term ``converted drug 
weight.''
    The Commission received comment expressing concern that the term 
``marihuana equivalency'' is misleading and results in confusion for 
individuals not fully versed in the guidelines. Some commenters 
suggested that the Commission should replace ``marihuana equivalency'' 
with another term.
    Specifically, the amendment adds the new term ``converted drug 
weight'' to all provisions of the Drug Quantity Table at Sec.  2D1.1(c) 
and changes the title of the ``Drug Equivalency Tables'' to ``Drug 
Conversion Tables.'' In addition, the amendment makes technical changes 
throughout the Guidelines Manual to account for the new term.
    This amendment is not intended as a substantive change in policy 
for Sec.  2D1.1.
    5. Amendment: Section 2L1.2(b)(2) is amended by striking ``If, 
before the defendant was ordered deported or ordered removed from the 
United States for the first time, the defendant sustained--'' and 
inserting ``If, before the defendant was ordered deported or ordered 
removed from the United States for the first time, the defendant 
engaged in criminal conduct that, at any time, resulted in--''.
    Section 2L1.2(b)(3) is amended by striking ``If, at any time after 
the defendant was ordered deported or ordered removed from the United 
States for the first time, the defendant engaged in criminal conduct 
resulting in--'' and inserting ``If, after the defendant was ordered 
deported or ordered removed from the United States for the first time, 
the defendant engaged in criminal conduct that, at any time, resulted 
in--''.
    The Commentary to Sec.  2L1.2 captioned ``Application Notes'' is 
amended--

in Note 2 in the paragraph that begins ```Sentence imposed' has the 
meaning'' by striking ``includes any term of imprisonment given upon 
revocation of probation, parole, or supervised release'' and inserting 
``includes any term of imprisonment given upon revocation of probation, 
parole, or supervised release, regardless of when the revocation 
occurred'';

in Note 4 by striking ``subsection (b)(3),'' and inserting ``subsection 
(b)(2) or (b)(3), as appropriate,'';

and by redesignating Notes 5 through 7 as Notes 6 through 8, 
respectively; and by inserting the following new Note 5:
    ``5. Cases in Which the Criminal Conduct Underlying a Prior 
Conviction Occurred Both Before and After the Defendant Was First 
Ordered Deported or Ordered Removed.--There may be cases in which the 
criminal conduct underlying a prior conviction occurred both before and 
after the defendant was ordered deported or ordered removed from the 
United States for the first time. For purposes of subsections (b)(2) 
and (b)(3), count such a conviction only under subsection (b)(2).''
    Reason for Amendment: This amendment responds to two application 
issues that arose after Sec.  2L1.2 (Unlawfully Entering or Remaining 
in the United States) was extensively amended in 2016. See USSG, App. 
C, Amendment 802 (effective Nov. 1, 2016).
    The specific offense characteristic at Sec.  2L1.2(b)(2) applies a 
sliding scale of enhancements, based on sentence length, if the 
``defendant sustained'' a ``conviction'' before being ordered removed 
for the first time. Correspondingly, Sec.  2L1.2(b)(3) applies a 
parallel scale of enhancements if the defendant ``engaged in criminal 
conduct resulting in'' a conviction ``at any time after'' the first 
order of removal. In most situations, any prior felony conviction that 
received criminal history points will qualify under either subsection 
(b)(2) or (b)(3), with the extent of the increase depending on the 
length of the sentence imposed. In some scenarios, a felony will not 
qualify for an upward adjustment under either subsection (b)(2) or 
(b)(3) even though it received criminal history points. Those scenarios 
occur when a defendant committed a crime before being ordered removed 
for the first time but was not convicted (or sentenced) for that crime 
until after that first order of removal.
    The amendment addresses this issue by establishing that the 
application of the Sec.  2L1.2(b)(2) enhancement depends on the timing 
of the underlying ``criminal conduct,'' and not on the timing of the 
resulting conviction. It does so by amending the first paragraph of 
subsection (b)(2) to state that the enhancement applies if pre-first 
removal conduct resulted in a conviction ``at any time,'' and makes a 
conforming change to the first paragraph of subsection (b)(3). In order 
to address how to treat an offense involving conduct that occurred both 
before and after a defendant's first order of removal, the amendment 
adds a new Application Note 5 explaining that an offense involving such 
conduct should be counted only under subsection (b)(2). The Commission 
determined that a defendant with a prior non-illegal reentry felony 
conviction that received criminal history points should receive

[[Page 20156]]

an enhancement for that conviction under either subsection (b)(2) or 
(b)(3). A defendant should not avoid an enhancement for an otherwise 
qualifying conviction because the conviction occurred after a 
defendant's first order of removal or deportation but was premised on 
conduct that occurred before that order. Because a conviction could be 
premised on conduct that occurred both before and after the first order 
of removal or deportation, the Commission adopted Application Note 5 to 
explain that such convictions are only counted once, under subsection 
(b)(2).
    The specific offense characteristics at Sec.  2L1.2(b)(2) and 
(b)(3) increase a defendant's offense level based on the length of the 
``sentence imposed'' for a prior felony conviction. An application note 
defines ``sentence imposed'' to mean ``sentence of imprisonment'' as 
that term is used in the criminal history guideline, Sec.  4A1.2. See 
USSG Sec.  2L1.2, comment. (n.2.). Consistent with that definition, the 
application note also directs that ``[t]he length of the sentence 
imposed includes any term of imprisonment given upon revocation of 
probation, parole, or supervised release.'' Id.
    Another part of the commentary to Sec.  2L1.2 directs that only 
convictions receiving criminal history points under ``Sec.  4A1.1(a), 
(b), or (c)'' (which assign points based on the length of the prior 
sentence imposed) are to be counted under Sec.  2L1.2(b). See USSG 
Sec.  2L1.2, comment. (n.3). In determining the length of a sentence 
for purposes of Chapter Four (and thus the number of criminal history 
points to be applied), the length of any term imposed on revocation of 
probation, parole, supervised release, or other similar status is added 
to the original term of imprisonment and the total term is used to 
calculate criminal history points under Sec.  4A1.1(a), (b), or (c). 
See USSG Sec.  4A1.2(k)(1).
    A Fifth Circuit opinion interpreted Sec.  2L1.2(b)(2) to bar 
consideration of a revocation that did not occur until after a 
defendant's first order of removal, even if the defendant was convicted 
prior to the first order of the removal. See United States v. Franco-
Galvan, 864 F.3d 338 (5th Cir. 2017). The court found that Application 
Note 2, despite its instruction that ``the length of the sentence 
imposed includes any term of imprisonment given upon revocation of 
probation, parole, or supervised release,'' was insufficiently clear to 
resolve the ``temporal'' question of when a revocation must occur, 
given that the Commission had resolved a prior circuit conflict in 2012 
by directing that revoked time should not be counted in the situation. 
See USSC, App. C, Amendment 764 (effective Nov. 1, 2012). A subsequent 
decision of the Ninth Circuit reached the same result. See United 
States v. Martinez, 870 F.3d 1163 (9th Cir. 2017). Although both cases 
involved an enhancement under subsection (b)(2), the same logic would 
seem to apply to enhancements under subsection (b)(3) when the 
conviction and revocation were separated by an intervening order of 
removal or deportation.
    The amendment resolves this issue by adding the clarifying phrase 
``regardless of when the revocation occurred'' to the definition of 
``sentence imposed'' in Application Note 2. The Commission determined 
that, consistent with the purposes of the 2016 amendment to Sec.  
2L1.2, the data underlying it, and the statement in Application Note 2, 
the length of a sentence imposed for purposes of Sec.  2L1.2(b)(2) and 
(b)(3) should include any additional term of imprisonment imposed upon 
revocation of probation, suspended sentence, or supervised release, 
regardless of whether the revocation occurred before or after the 
defendant's first (or any subsequent) order of removal. As the reason 
for amendment for Amendment 802 explained, ``[t]he Commission 
determined that a sentence-imposed approach is consistent with the 
Chapter Four criminal history rules, easily applied, and appropriately 
calibrated to account for the seriousness of prior offenses.'' USSC, 
App. C, Amendment 802 (effective Nov. 1, 2016). Excluding sentence 
length added by post-removal revocations would be inconsistent with the 
purpose of Amendment 802 and its underlying data analysis. Id.
    6. Amendment: The Commentary to Sec.  3E1.1 captioned ``Application 
Notes'' is amended in Note 1(A) by striking ``However, a defendant who 
falsely denies, or frivolously contests, relevant conduct that the 
court determines to be true has acted in a manner inconsistent with 
acceptance of responsibility'' and inserting ``A defendant who falsely 
denies, or frivolously contests, relevant conduct that the court 
determines to be true has acted in a manner inconsistent with 
acceptance of responsibility, but the fact that a defendant's challenge 
is unsuccessful does not necessarily establish that it was either a 
false denial or frivolous''.
    Reason for Amendment: This amendment responds to concerns that some 
courts have interpreted the commentary to Sec.  3E1.1 (Acceptance of 
Responsibility) to automatically preclude application of the 2-level 
reduction for acceptance of responsibility when the defendant makes an 
unsuccessful good faith, non-frivolous challenge to relevant conduct. 
Application Note 1 provides a non-exhaustive list of appropriate 
considerations in determining whether a defendant has clearly 
demonstrated acceptance of responsibility. Among those considerations 
is whether the defendant truthfully admitted the conduct comprising the 
offense(s) of conviction and truthfully admitted or did not falsely 
deny any additional relevant conduct for which the defendant is 
accountable under Sec.  1B1.3 (Relevant Conduct). See USSG Sec.  3E1.1, 
comment. (n.1(A)). The application note further provides that ``a 
defendant who falsely denies, or frivolously contests, relevant conduct 
that the court determines to be true has acted in a manner inconsistent 
with acceptance of responsibility.'' The amendment clarifies that an 
unsuccessful challenge to relevant conduct does not necessarily 
establish that the challenge was either a false denial or frivolous. 
Specifically, the amendment adds ``but the fact that a defendant's 
challenge is unsuccessful does not necessarily establish that it was 
either a false denial or frivolous'' to the end of Application Note 
1(A).
    7. Amendment: The Commentary to Sec.  5C1.1 captioned ``Application 
Notes'' is amended by redesignating Notes 4 through 9 as Notes 5 
through 10, respectively; and by inserting the following new Note 4:
    ``4. If the defendant is a nonviolent first offender and the 
applicable guideline range is in Zone A or B of the Sentencing Table, 
the court should consider imposing a sentence other than a sentence of 
imprisonment, in accordance with subsection (b) or (c)(3). See 28 
U.S.C. 994(j). For purposes of this application note, a `nonviolent 
first offender' is a defendant who has no prior convictions or other 
comparable judicial dispositions of any kind and who did not use 
violence or credible threats of violence or possess a firearm or other 
dangerous weapon in connection with the offense of conviction. The 
phrase `comparable judicial dispositions of any kind' includes 
diversionary or deferred dispositions resulting from a finding or 
admission of guilt or a plea of nolo contendere and juvenile 
adjudications.''.
    The Commentary to Sec.  5F1.2 captioned ``Application Notes'' is 
amended in Note 1 by striking ``Electronic monitoring is an appropriate 
means of surveillance and ordinarily should be used in connection with 
home detention'' and inserting ``Electronic monitoring is an 
appropriate means of

[[Page 20157]]

surveillance for home detention''; and by striking ``alternative means 
of surveillance may be used so long as they are as effective as 
electronic monitoring'' and inserting ``alternative means of 
surveillance may be used if appropriate''.
    The Commentary to Sec.  5F1.2 captioned ``Background'' is amended 
by striking ``The Commission has concluded that the surveillance 
necessary for effective use of home detention ordinarily requires 
electronic monitoring'' and inserting ``The Commission has concluded 
that electronic monitoring is an appropriate means of surveillance for 
home detention''; and by striking ``the court should be confident that 
an alternative form of surveillance will be equally effective'' and 
inserting ``the court should be confident that an alternative form of 
surveillance is appropriate considering the facts and circumstances of 
the defendant's case''.
    Section 5H1.3 is amended by striking ``See Sec.  5C1.1, Application 
Note 6'' and inserting ``See Sec.  5C1.1, Application Note 7''.
    Section 5H1.4 is amended by striking ``See Sec.  5C1.1, Application 
Note 6'' and inserting ``See Sec.  5C1.1, Application Note 7''.
    Reason for Amendment: The amendment adds a new application note to 
the Commentary at Sec.  5C1.1 (Imposition of a Term of Imprisonment), 
which states that if a defendant is a ``nonviolent first offender and 
the applicable guideline range is in Zone A or B of the Sentencing 
Table, the court should consider imposing a sentence other than a 
sentence of imprisonment.'' This new application note is consistent 
with the statutory language in 28 U.S.C. 994(j) regarding the ``general 
appropriateness of imposing a sentence other than imprisonment'' for 
``a first offender who has not been convicted of a crime of violence or 
an otherwise serious offense'' and cites the statutory provision in 
support. It also is consistent with a recent Commission recidivism 
study, which demonstrated that offenders with zero criminal history 
points have a lower recidivism rate than offenders with one criminal 
history point, and that offenders with zero criminal history points and 
no prior contact with the criminal justice system have an even lower 
recidivism rate. See Tracey Kyckelhahn & Trishia Cooper, U.S. 
Sentencing Comm'n, The Past Predicts the Future: Criminal History and 
Recidivism of Federal Offenders at 6-9 (2017).
    Where permitted by statute, the Guidelines Manual provides for non-
incarceration sentences for offenders in Zones A and B of the 
Sentencing Table. Zone A (in which all sentencing ranges are zero to 
six months regardless of criminal history category) permits the full 
spectrum of sentencing options: (1) A fine only; (2) a term of 
probation only; (3) probation with conditions of confinement (home 
detention, community confinement, or intermittent confinement); (4) a 
``split sentence'' (a term of imprisonment followed by a term of 
supervised release with condition of confinement that substitutes for a 
portion of the guideline term); or (5) a term of imprisonment only. 
Zone B (which includes sentencing ranges that have a low-end of one 
month and a high-end of 15 months, and vary by criminal history 
category) also authorizes non-prison sentences. However, Zone B 
sentencing options are more restrictive, authorizing (1) probation with 
conditions of confinement; (2) a ``split sentence''; or (3) a term of 
imprisonment only. Consistent with the statutory mandate in section 
994(j), the application note is intended to serve as a reminder to 
courts to consider imposing non-incarceration sentences for a defined 
class of ``nonviolent first offenders'' whose applicable guideline 
ranges are in Zones A or B of the Sentencing Table.
    For purposes of the new application note, the amendment defines a 
``nonviolent first offender'' as a defendant who (1) has no prior 
convictions or other comparable judicial dispositions of any kind; and 
(2) did not use violence or credible threats of violence or possess a 
firearm or other dangerous weapon in connection with the offense. It 
explains that ``comparable judicial dispositions of any kind'' includes 
``diversionary or deferred dispositions resulting from a finding or 
admission of guilt or a plea of nolo contendere and juvenile 
adjudications.''
    The amendment adopts language from the statutory and guidelines 
``safety-valve'' provisions to exclude offenders who ``use[d] violence 
or credible threats of violence or possess[ed] a firearm or other 
dangerous weapon in connection with the offense.'' See 18 U.S.C. 
3553(f)(2); USSG Sec.  5C1.2(a)(2). This real-offense definition of 
``violent'' offense avoids the complicated application of the 
``categorical approach'' to determine whether an offense qualifies as 
``violent.'' See United States v. Starks, 861 F.3d 306, 324 (1st Cir. 
2017) (describing the ``immensely complicated analysis required by the 
categorical approach''); see also USSG Sec.  5C1.2, comment. (n.3) 
(noting that the determination of whether ``the offense'' was violent 
or involved a firearm requires a court to consider not only the offense 
of conviction but also ``all relevant conduct''). It also ensures that 
only nonviolent offenders are covered by the new application note.
    The amendment also deletes language from the commentary to Sec.  
5F1.2 (Home Detention) that generally encouraged courts to use 
electronic monitoring (also called location monitoring) when home 
detention is made a condition of supervision, and instead instructs 
that electronic monitoring or any alternative means of surveillance may 
each be used, as ``appropriate.'' The goal of this change is to 
increase the use of probation with home detention as an alternative to 
incarceration. The Commission received testimony indicating that 
location monitoring is resource-intensive and otherwise demanding on 
probation officers. Additionally, it heard testimony that imposing 
location monitoring by default is inconsistent with the evidence-based 
``risk-needs-responsivity'' (RNR) model of supervision and may be 
counterproductive for certain lower-risk offenders. For many low-risk 
offenders, less intensive surveillance methods (e.g., telephonic 
contact, video conference, unannounced home visits by probation 
officers) are sufficient to enforce home detention. The revised 
language would allow probation officers and courts to exercise 
discretion to use surveillance methods that they deem appropriate in 
light of evidence-based practices.
    8. Amendment: The Commentary to Sec.  2A3.5 captioned ``Statutory 
Provision'' is amended by striking ``Sec.  2250(a)'' and inserting 
``Sec.  2250(a), (b)''.
    The Commentary to Sec.  2A3.5 captioned ``Application Notes'' is 
amended by redesignating Note 2 as Note 3; and by inserting the 
following new Note 2:
    ``2. Application of Subsection (b)(1).--For purposes of subsection 
(b)(1), a defendant shall be deemed to be in a `failure to register 
status' during the period in which the defendant engaged in conduct 
described in 18 U.S.C. 2250(a) or (b).''.
    Section 2A3.6(a) is amended by striking ``Sec.  2250(c)'' and 
inserting ``Sec.  2250(d)''.
    The Commentary to Sec.  2A3.6 captioned ``Statutory Provisions'' is 
amended by striking ``2250(c)'' and inserting ``2250(d)''.
    The Commentary to Sec.  2A3.6 captioned ``Application Notes'' is 
amended--

in Note 1 by striking ``Section 2250(c)'' and inserting ``Section 
2250(d)''; and by inserting after ``18 U.S.C. 2250(a)'' the following: 
``or (b)'';

in Note 3 by striking ``Sec.  2250(c)'' and inserting ``Sec.  
2250(d)'';


[[Page 20158]]


and in Note 4 by striking ``Sec.  2250(c)'' and inserting ``Sec.  
2250(d)''.
    Section 2B5.3(b)(5) is amended by striking ``counterfeit drug'' and 
inserting ``drug that uses a counterfeit mark on or in connection with 
the drug''.
    The Commentary to Sec.  2B5.3 captioned ``Application Notes'' is 
amended in Note 1 by striking the third undesignated paragraph as 
follows:
    `` `Counterfeit drug' has the meaning given that term in 18 U.S.C. 
2320(f)(6).'';

and by inserting after the paragraph that begins `` `Counterfeit 
military good or service' has the meaning'' the following new 
paragraph:
    `` `Drug' and `counterfeit mark' have the meaning given those terms 
in 18 U.S.C. 2320(f).''.
    The Commentary to Sec.  2G1.3 captioned ``Application Notes'' is 
amended in Note 4 by striking ``(b)(3)'' each place such term appears 
and inserting ``(b)(3)(A)''.
    Section 5D1.3(a)(6)(A) is amended by striking ``18 U.S.C. 2248, 
2259, 2264, 2327, 3663, 3663A, and 3664'' and inserting ``18 U.S.C. 
3663 and 3663A, or any other statute authorizing a sentence of 
restitution''.
    Appendix A (Statutory Index) is amended--

in the line referenced to 15 U.S.C. 2615 by striking ``Sec.  2615'' and 
inserting ``Sec.  2615(b)(1)'';

by inserting before the line referenced to 15 U.S.C. 6821 the following 
new line reference:

``15 U.S.C. 2615(b)(2) 2Q1.1'';

in the line referenced to 18 U.S.C. 2250(a) by striking ``Sec.  
2250(a)'' and inserting ``Sec.  2250(a), (b)'';

and in the line referenced to 18 U.S.C. 2250(c) by striking ``Sec.  
2250(c)'' and inserting ``Sec.  2250(d)''.
    Reason for Amendment: This multi-part amendment responds to 
recently enacted legislation and miscellaneous guideline application 
issues.
    First, the amendment responds to section 6 of the International 
Megan's Law to Prevent Child Exploitation and Other Sexual Crimes 
Through Advanced Notification of Traveling Sex Offenders, Public Law 
114-119 (Feb. 8, 2016), which added a new registration requirement for 
certain sex offenders required to register under the Sex Offender 
Registration and Notification Act (SORNA) at 34 U.S.C. 20914. SORNA 
requires sex offenders to register in the sex offender registry, and 
keep their registration current, by providing certain identifying 
information including names, addresses, and Social Security Numbers. 
The new requirement at 34 U.S.C. 20914(7) directs sex offenders to 
provide information relating to intended travel outside the United 
States, including any anticipated dates and places of departure, 
arrival or return, air carrier and flight numbers, and destination 
country. The Act also established a new offense at 18 U.S.C. 2250(b). 
For those required to register under SORNA, knowingly failing to 
provide this travel-related information and engaging or attempting to 
engage in the intended travel outside of the United States, carries a 
statutory maximum of 10 years of imprisonment. Section 2250 offenses 
are referenced in Appendix A (Statutory Index) to Sec.  2A3.5 (Failure 
to Register as a Sex Offender). The amendment amends Appendix A so the 
new offense at 18 U.S.C. 2250(b) is referenced to Sec.  2A3.5. The 
amendment also adds a new Application Note 2 to the Commentary to Sec.  
2A3.5 providing that for purposes of Sec.  2A3.5(b)(1), a defendant 
shall be considered in a ``failure to register status'' during the time 
the defendant engaged in conduct described in either section 2250(a) 
(failing to register or update registration) or section 2250(b) 
(failing to provide required travel-related information). This 
application note reflects the Commission's determination that failing 
to provide information about intended foreign travel meets the 
definition of failing to update registration information in the sex 
offender registry. In addition, the amendment makes clerical changes to 
Sec.  2A3.6 (Aggravated Offenses Relating to Registration as a Sex 
Offender) to reflect the adoption of section 2250(b) and the associated 
redesignation of section 2250(c) as section 2250(d).
    Second, the amendment responds to section 3 of the Transnational 
Drug Trafficking Act of 2016, Public Law 114-154 (May 16, 2016), which 
made changes relating to the trafficking of counterfeit drugs by 
amending the language in the penalty provision at 18 U.S.C. 2320. The 
Act amended section 2320(b)(3) to replace the term ``counterfeit drug'' 
with the phrase ``a drug that uses a counterfeit mark on or in 
connection with the drug.'' The Act also revised section 2320(f) to 
define the term ``drug'' by reference to the term as defined in the 
Federal Food, Drug, and Cosmetic Act found at 21 U.S.C. 321. Section 
2320 offenses are referenced in Appendix A (Statutory Index) to Sec.  
2B5.3 (Criminal Infringement of Copyright or Trademark). The amendment 
replaces the term ``counterfeit drug'' at Sec.  2B5.3(b)(5) with the 
new phrase in the revised section 2320(b)(3), to remain consistent with 
the language of the statute. Similarly, the amendment amends the 
commentary to Sec.  2B5.3 to remove a definition for the obsolete term 
``counterfeit drug'' and replace it with definitions of the terms 
``drug'' and ``counterfeit mark'' as found in the revised statute.
    Third, the amendment responds to section 12 of the Frank R. 
Lautenberg Chemical Safety for the 21st Century Act of 2016, Public Law 
114-182 (June 22, 2016), which amended section 16 of the Toxic 
Substances Control Act (15 U.S.C. 2615) by adding a new provision at 
section 2615(b)(2). The new provision prohibits any person from 
knowingly and willfully violating specific provisions of the Toxic 
Substances Control Act, knowing at the time of the violation that the 
violation puts a person in imminent danger of death or bodily injury, 
with a maximum penalty of 15 years of imprisonment. The Toxic 
Substances Control Act is referenced in Appendix A (Statutory Index) to 
Sec.  2Q1.2 (Mishandling of Hazardous or Toxic Substances of 
Pesticides; Recordkeeping, Tampering, and Falsification; Unlawfully 
Transporting Hazardous Materials in Commerce). The amendment continues 
to reference the preexisting offense, now codified at section 
2615(b)(1), to Sec.  2Q1.2, but references the new offense, codified at 
section 2615(b)(2), to Sec.  2Q1.1 (Knowing Endangerment Resulting From 
Mishandling Hazardous or Toxic Substances, Pesticides or Other 
Pollutants). The Commission determined Sec.  2Q1.1 is the most 
analogous guideline because it covers similar ``knowing endangerment'' 
provisions and has a similar mens rea element found in similar statutes 
referenced in Appendix A to Sec.  2Q1.1.
    Fourth, the amendment responds to section 2 of the Justice for All 
Reauthorization Act of 2016, Public Law 114-324 (Dec. 16, 2016), which 
amended 18 U.S.C. 3583(d) (relating to conditions of supervised 
release) to require a court, when imposing a sentence of supervised 
release, to include as a condition that the defendant make restitution 
in accordance with sections 3663 and 3663A of Title 18 of the United 
States Code, or any other statute authorizing a sentence of 
restitution. The amendment amends subsection (a)(6)(A) of Sec.  5D1.3 
(Conditions of Supervised Release) to include a mandatory condition of 
supervised release in conformance with the new statutory requirement. 
The amendment also parallels the Judicial Conference of the United 
States' recent revision of the Judgment in a Criminal Case form to 
include a new mandatory condition of supervised release.

[[Page 20159]]

    Fifth, the amendment clarifies an application issue that has arisen 
with respect to Sec.  2G1.3 (Promoting a Commercial Sex Act or 
Prohibited Sexual Conduct with a Minor; Transportation of Minors to 
Engage in a Commercial Sex Act or Prohibited Sexual Conduct; Travel to 
Engage in Commercial Sex Act or Prohibited Sexual Conduct with a Minor; 
Sex Trafficking of Children; Use of Interstate Facilities to Transport 
Information about a Minor), which applies to several offenses involving 
the transportation of a minor for illegal sexual activity. A two-level 
enhancement at Sec.  2G1.3(b)(3) applies if the offense involved the 
use of a computer to either (A) persuade, entice or coerce a minor, or 
to facilitate the travel of a minor, to engage in prohibited sexual 
conduct, or (B) to entice, offer, or solicit a person to engage in 
prohibited sexual conduct with a minor. While Application Note 4 sets 
forth guidance on this enhancement, it fails to distinguish between the 
two prongs of subsection (b)(3). As a result, an application issue has 
arisen regarding whether the note prohibits application of the 
enhancement where a computer was used to solicit a third party to 
engage in prohibited sexual conduct with a minor, as set out in 
subsection (b)(3)(B). Courts have concluded that the application note 
is inconsistent with the language of Sec.  2G1.3(b)(3), and that 
application of the enhancement for the use of a computer in third party 
solicitation cases is proper. See e.g., United States v. Cramer, 777 
F.3d 597, 606 (2d Cir. 2015); United States v. McMillian, 777 F.3d 444, 
449-50 (7th Cir. 2015); United States v. Hill, 782 F.3d 842, 846 (11th 
Cir. 2015); United States v. Pringler, 765 F.3d 455 (5th Cir. 2014). 
The amendment is intended to clarify the Commission's original intent 
that Application Note 4 apply only to subsection (b)(3)(A).
    9. Amendment: Chapter One, Part A is amended--
    in Subpart 1(4)(b) (Departures) by inserting an asterisk after 
``Sec.  5K2.19 (Post-Sentencing Rehabilitative Efforts)''; and by 
inserting after the first paragraph the following note:
    ``*Note: Section 5K2.19 (Post-Sentencing Rehabilitative Efforts) 
was deleted by Amendment 768, effective November 1, 2012. (See USSG 
App. C, amendment 768.)'';

and in the note at the end of Subpart 1(4)(d) (Probation and Split 
Sentences) by striking ``Supplement to Appendix C'' and inserting 
``USSG App. C''.
    The Commentary to Sec.  1B1.13 captioned ``Application Notes'' is 
amended in Note 4 by striking ``factors set forth 18 U.S.C. 3553(a)'' 
and inserting ``factors set forth in 18 U.S.C. 3553(a)''.
    The Commentary to Sec.  2A3.5 captioned ``Application Notes'' is 
amended in Note 1 in the paragraph that begins `` `Sex offense' has the 
meaning'' by striking ``42 U.S.C. 16911(5)'' and inserting ``34 U.S.C. 
20911(5)''; and in the paragraph that begins `` `Tier I offender', 
`Tier II offender', and `Tier III offender' have the meaning'' by 
striking ``42 U.S.C. 16911'' and inserting ``34 U.S.C. 20911''.
    The Commentary to Sec.  2B1.1 captioned ``Application Notes'' is 
amended in Note 2(A)(i) by striking ``as determined under the 
provisions of Sec.  1B1.2 (Applicable Guidelines) for the offense of 
conviction'' and inserting the following: ``specifically referenced in 
Appendix A (Statutory Index) for the offense of conviction, as 
determined under the provisions of Sec.  1B1.2 (Applicable 
Guidelines)''.
    The Commentary to Sec.  2B1.5 captioned ``Application Notes'' is 
amended--

in Note 1(A) by striking clause (ii) and redesignating clauses (iii) 
through (vii) as clauses (ii) through (vi), respectively;

in Note 1(A)(i) by striking ``16 U.S.C. 470w(5)'' and inserting ``54 
U.S.C. 300308'';

in Note 3(C) by striking ``16 U.S.C. 470a(a)(1)(B)'' and inserting ``54 
U.S.C. 302102'';

in Note 3(E) by striking ``the Antiquities Act of 1906 (16 U.S.C. 
431)'' and inserting ``54 U.S.C. 320301'';

and in Note 3(F) by striking ``16 U.S.C. 1c(a)'' and inserting ``54 
U.S.C. 100501''.
    Section 2D1.11 is amended in subsection (d)(6) by striking 
``Pseuodoephedrine'' and inserting ``Pseudoephedrine''; and in 
subsection (e)(2), under the heading relating to List I Chemicals, by 
striking the period at the end and inserting a semicolon.
    The Commentary to Sec.  2M2.1 captioned ``Statutory Provisions'' is 
amended by striking ``Sec.  2153'' and inserting ``Sec. Sec.  2153''; 
and by inserting at the end the following: ``For additional statutory 
provision(s), see Appendix A (Statutory Index).''.
    The Commentary to Sec.  2Q1.1 captioned ``Statutory Provisions'' is 
amended by striking ``42 U.S.C. 6928(e)'' and inserting ``42 U.S.C. 
6928(e), 7413(c)(5)''; and by inserting at the end the following: ``For 
additional statutory provision(s), see Appendix A (Statutory Index).''.
    The Commentary to Sec.  2Q1.2 captioned ``Statutory Provisions'' is 
amended by striking ``7413'' and inserting ``7413(c)(1)-(4)''.
    The Commentary to Sec.  2Q1.3 captioned ``Statutory Provisions'' is 
amended by striking ``7413'' and inserting ``7413(c)(1)-(4)''.
    The Commentary to Sec.  2Q1.3 captioned ``Application Notes'' is 
amended in Note 8 by striking ``Adequacy of Criminal History Category'' 
and inserting ``Departures Based on Inadequacy of Criminal History 
Category (Policy Statement)''.
    The Commentary to Sec.  2R1.1 captioned ``Application Notes'' is 
amended in Note 7 by striking ``Adequacy of Criminal History Category'' 
and inserting ``Departures Based on Inadequacy of Criminal History 
Category (Policy Statement)''.
    The Commentary to Sec.  2X5.2 captioned ``Statutory Provisions'' is 
amended by striking ``42 U.S.C. 14133'' and inserting ``34 U.S.C. 
12593''.
    Section 4A1.2 is amended in subsections (h), (i), and (j) by 
striking ``Adequacy of Criminal History Category'' each place such term 
appears and inserting ``Departures Based on Inadequacy of Criminal 
History Category (Policy Statement)''.
    The Commentary to Sec.  4A1.2 captioned ``Application Notes'' is 
amended in Notes 6 and 8 by striking ``Adequacy of Criminal History 
Category'' both places such term appears and inserting ``Departures 
Based on Inadequacy of Criminal History Category (Policy Statement)''.
    The Commentary to Sec.  4B1.4 captioned ``Background'' is amended 
by striking ``Adequacy of Criminal History Category'' and inserting 
``Departures Based on Inadequacy of Criminal History Category (Policy 
Statement)''.
    Section 5B1.3(a)(10) is amended by striking ``42 U.S.C. 14135a'' 
and inserting ``34 U.S.C. 40702''.
    Section 5D1.3 is amended in subsection (a)(4) by striking ``release 
on probation'' and inserting ``release on supervised release''; and in 
subsection (a)(8) by striking ``42 U.S.C. 14135a'' and inserting ``34 
U.S.C. 40702''.
    Section 8C2.1(a) is amended by striking ``Sec. Sec.  2C1.1, 2C1.2, 
2C1.6'' and inserting ``Sec. Sec.  2C1.1, 2C1.2''.
    Appendix A (Statutory Index) is amended--

by striking the line referenced to 16 U.S.C. 413;

in the line referenced to 18 U.S.C. 371 by rearranging the guidelines 
to place them in proper numerical order;

in the line referenced to 18 U.S.C. 1591 by rearranging the guidelines 
to place them in proper numerical order;


[[Page 20160]]


by inserting after the line referenced to 18 U.S.C. 1864 the following 
new line reference:

 
 
 
``18 U.S.C. 1865(c)                  2B1.1'';
 

by inserting after the line referenced to 33 U.S.C. 3851 the following 
new line references:

 
 
 
``34 U.S.C. 10251                    2B1.1
34 U.S.C. 10271                      2B1.1
34 U.S.C. 12593                      2X5.2
34 U.S.C. 20962                      2H3.1
34 U.S.C. 20984                      2H3.1'';
 

and by striking the lines referenced to 42 U.S.C. 3791, 42 U.S.C. 3795, 
42 U.S.C. 14133, 42 U.S.C. 16962, and 42 U.S.C. 16984.
    Reason for Amendment: This amendment makes various technical 
changes to the Guidelines Manual.
    First, the amendment sets forth clarifying changes to two 
guidelines. The amendment amends Chapter One, Part A, Subpart 1(4)(b) 
(Departures) to provide an explanatory note addressing the fact that 
Sec.  5K2.19 (Post-Sentencing Rehabilitative Efforts) was deleted by 
Amendment 768, effective November 1, 2012. The amendment also makes 
minor clarifying changes to Application Note 2(A) to Sec.  2B1.1 
(Theft, Property Destruction, and Fraud), to make clear that, for 
purposes of subsection (a)(1)(A), an offense is ``referenced to this 
guideline'' if Sec.  2B1.1 is the applicable Chapter Two guideline 
specifically referenced in Appendix A (Statutory Index) for the offense 
of conviction.
    Second, the amendment makes technical changes to provide updated 
references to certain sections in the United States Code that were 
restated in legislation. As part of an Act to codify existing law 
relating to the National Park System, Congress repealed numerous 
sections in Title 16 of the United States Code, and restated them in 
Title 18 and a newly enacted Title 54. See Public Law 113-287 (Dec. 19, 
2014). The amendment amends the Commentary to Sec.  2B1.5 (Theft of, 
Damage to, or Destruction of, Cultural Heritage Resources or 
Paleontological Resources; Unlawful Sale, Purchase, Exchange, 
Transportation, or Receipt of Cultural Heritage Resources or 
Paleontological Resources) to correct outdated references to certain 
sections in Title 16 that were restated, with minor revisions, when 
Congress enacted Title 54. It also deletes from the Commentary to Sec.  
2B1.5 the provision relating to the definition of ``historic 
resource,'' as that term was omitted from Title 54. In addition, the 
amendment makes a technical change to Appendix A (Statutory Index), to 
correct an outdated reference to 16 U.S.C. 413 by replacing it with the 
appropriate reference to 18 U.S.C. 1865(c).
    Third, the amendment makes additional technical changes to reflect 
the editorial reclassification of certain sections in the United States 
Code. Effective September 1, 2017, the Office of Law Revision Counsel 
transferred certain provisions bearing on crime control and law 
enforcement, previously scattered throughout various parts of the 
United States Code, to a new Title 34. To reflect the new section 
numbers of the reclassified provisions, the amendment makes changes to: 
The Commentary to Sec.  2A3.5 (Failure to Register as a Sex Offender); 
the Commentary to Sec.  2X5.2 (Class A Misdemeanors (Not Covered by 
Another Specific Offense Guideline)); subsection (a)(10) of Sec.  5B1.3 
(Conditions of Probation); subsection (a)(8) of Sec.  5D1.3 (Conditions 
of Supervised Release); and Appendix A (Statutory Index).
    Fourth, the amendment makes clerical changes in Sec. Sec.  2Q1.3 
(Mishandling of Other Environmental Pollutants; Recordkeeping, 
Tampering, and Falsification), 2R1.1 (Bid-Rigging, Price-Fixing or 
Market-Allocation Agreements Among Competitors), 4A1.2 (Definitions and 
Instructions for Computing Criminal History), and 4B1.4 (Armed Career 
Criminal), to correct title references to Sec.  4A1.3 (Departures Based 
on Inadequacy of Criminal History Category (Policy Statement)).
    Finally, the amendment also makes clerical changes to--
     the Commentary to Sec.  1B1.13 (Reduction in Term of 
Imprisonment Under 18 U.S.C. 3582(c)(1)(A) (Policy Statement)), by 
inserting a missing word in Application Note 4;
     subsection (d)(6) to Sec.  2D1.11 (Unlawfully 
Distributing, Importing, Exporting or Possessing a Listed Chemical; 
Attempt or Conspiracy), by correcting a typographical error in the line 
referencing Pseudoephedrine;
     subsection (e)(2) to Sec.  2D1.11 (Unlawfully 
Distributing, Importing, Exporting or Possessing a Listed Chemical; 
Attempt or Conspiracy), by correcting a punctuation mark under the 
heading relating to List I Chemicals;
     the Commentary to Sec.  2M2.1 (Destruction of, or 
Production of Defective, War Material, Premises, or Utilities) 
captioned ``Statutory Provisions,'' by adding a missing section symbol 
and a reference to Appendix A (Statutory Index);
     the Commentary to Sec.  2Q1.1 (Knowing Endangerment 
Resulting From Mishandling Hazardous or Toxic Substances, Pesticides or 
Other Pollutants) captioned ``Statutory Provisions,'' by adding a 
missing reference to 42 U.S.C. 7413(c)(5) and a reference to Appendix A 
(Statutory Index);
     the Commentary to Sec.  2Q1.2 (Mishandling of Hazardous or 
Toxic Substances or Pesticides; Recordkeeping, Tampering, and 
Falsification; Unlawfully Transporting Hazardous Materials in Commerce) 
captioned ``Statutory Provisions,'' by adding a specific reference to 
42 U.S.C. 7413(c)(1)-(4);
     the Commentary to Sec.  2Q1.3 (Mishandling of Other 
Environmental Pollutants; Recordkeeping, Tampering, and Falsification) 
captioned ``Statutory Provisions,'' by adding a specific reference to 
42 U.S.C. 7413(c)(1)-(4);
     subsection (a)(4) to Sec.  5D1.3. (Conditions of 
Supervised Release), by changing an inaccurate reference to 
``probation'' to ``supervised release'';
     subsection (a) of Sec.  8C2.1 (Applicability of Fine 
Guidelines), by deleting an outdated reference to Sec.  2C1.6, which 
was deleted by consolidation with Sec.  2C1.2 (Offering, Giving, 
Soliciting, or Receiving a Gratuity) effective November 1, 2004; and
     the lines referencing ``18 U.S.C. 371'' and ``18 U.S.C. 
1591'' in Appendix A (Statutory Index), by rearranging the order of 
certain Chapter Two guidelines references to place them in proper 
numerical order.

[FR Doc. 2018-09549 Filed 5-4-18; 8:45 am]
 BILLING CODE 2210-40-P